Skip to content

Immersive Virtual Reality Meditation in Voice Therapy

Immediate and Cumulative Effects of Meditation on Voice Therapy Using Immersive Virtual Reality (IVR)

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07176013
Enrollment
60
Registered
2025-09-16
Start date
2025-09-03
Completion date
2026-12-30
Last updated
2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Voice Disorders

Keywords

Virtual Reality, Immersive, Mindfulness, Meditation, Voice

Brief summary

This study aims to explore the feasibility of incorporating regular guided meditations via immersive virtual reality (IVR) at the start of voice therapy sessions to facilitate better learning and retention of treatment. The study will involve 30 participants, and use the TRIPP application with the Meta Quest 2 virtual reality headset, known for its immersive meditation experiences designed to calm or focus the user. The objective is to investigate the immediate effects of meditation/mindfulness in IVR on vocal production, with the goal of improving self-regulation, attentional focus, and reducing vocal hyperfunction. IVR has been utilized in mental health settings and exposure therapy for various conditions, but its application in voice therapy, particularly for anxiety reduction through fully immersive meditation, remains unexplored. The study seeks to determine whether IVR can enhance therapy outcomes by improving engagement, attention, and vocal control in individuals undergoing voice therapy, potentially maximizing treatment gains. Through this research, the aim is to assess the efficacy of IVR in enhancing voice therapy interventions and addressing the unique challenges posed by stress and anxiety in voice users.

Interventions

BEHAVIORALVoice therapy

All patients will receive a course of voice therapy as normal.

BEHAVIORALMeditation

Meditation at the start of each session. (each session is 30 minutes)

DEVICEVirtual Reality

TRIPP application in the Meta Quest 2 Virtual Reality Headset.

Sponsors

Icahn School of Medicine at Mount Sinai
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients with voice disorders, difficulties or laryngeal hypersensitivity, and who also have anxiety * Must have availability to participate for entire course of 5 consistent weeks

Exclusion criteria

* Anyone not meeting inclusion criteria * Presence of any additional medical condition significantly affecting: * Respiratory function (e.g., advanced lung disease) * Laryngeal function (e.g., status-post deep brain stimulation) * Lingual function * Velopharyngeal function (e.g., laryngectomy)

Design outcomes

Primary

MeasureTime frameDescription
Maximum Phonation Time (MPT)at each therapy session (approximately 1 week apart over 4 weeks)MPT will be used to assess participants' maximum phonation time. The speech evaluator instructs the patient to take a comfortable breath and then produce the sound /a/ for as long as possible. The task is performed twice, and the maximum duration of the two measurements is used.
Noise-to-Harmonic Ratio (NHR)Pre-intervention (within 1 week before first session) and post-intervention (within 1 week after final sessionNHR is a parameter in MDVP that represents ratio of non-harmonic and harmonic waves in a certain sound wave period. NHR describes the quality of the amount of noise in the sound. Inadequate closure of the vocal cords and periodic vibrations of the vocal cords cause excessive air flow as it passes through the vocal cords, causing turbulence and noise. Normal and periodic sound signals will have a small NHR, while dysphonia sound signals will have a large NHR value.
Cepstral Peak Prominence (CPPS)Pre-intervention (within 1 week before first session) and post-intervention (within 1 week after final sessionCepstral Peak Prominence (CPPS) is an indicator of voice quality. It is measured in decibels. An increase in CPPS value indicates an improvement in voice symptoms.
Acoustic Vocal Quality Index (AVQI)Pre-intervention (within 1 week before first session) and post-intervention (within 1 week after final sessionThe acoustic voice quality index (AVQI) is a multiparametric score to quantify vocal quality. It is based on a weighted combination of 6 voice parameters: smoothed cepstral peak prominence (CPPS), harmonics-to-noise ratio (HNR), shimmer local (SL), shimmer local dB (SLdB), general slope of the spectrum (slope) and tilt of the regression line through the spectrum (tilt). The formula is constructed as 9.072 - 0.245 × CPPs - 0.161 × HNR - 0.470 × SL + 6.158 × SLdB - 0.071 × Slope - 0.170 × Tilt and ranges from 0 to 10. A lower score correlates with a better vocal quality.

Secondary

MeasureTime frameDescription
Voice Handicap IndexPre-intervention (within 1 week before first session) and post-intervention (within 1 week after final sessionThe Voice Handicap Index (VHI) is a validated 10-item questionnaire measuring the impact of voice challenges on quality of life (QOL). Scores range from 0 to 40, with higher scores indicating greater perceived voice handicap and negative impact on daily functioning.
State Trait Anxiety Inventory Y-1 (STAI-1), long formPre-intervention (within 1 week before first session) and post-intervention (within 1 week after final sessionThe State Anxiety Inventory (STAI Y-1) long form assess the severity of current state of anxiety in the moment, with a minimum score of 40 and max of 80, where scores \>37 indicates moderate-severe state anxiety. Higher score indicates more severity of anxiety
State Trait Anxiety Inventory Y-1 (STAY Y-1), short formImmediately pre- and immediately post-meditation in each therapy session, over approximately 4 weeksThe State Anxiety Inventory-Short Form (STAI Y-1) assesses severity of current state of anxiety in the moment to determine immediate effects of meditation. Scores range from 20-40. Higher score indicates more severity of anxiety.
State Trait Anxiety Inventory Y-2 (STAI Y-2), long formPre-intervention (within 1 week before first session) and post-intervention (within 1 week after final sessionThe State Trait Anxiety Inventory (STAI Y-2) assesses severity of anxiety relative to how the patient "generally" feels. Scores range 40-80, with scores \>37 indicating moderate-severe trait anxiety. Higher score indicates more severity of anxiety.
Vocal Fatigue IndexPre-intervention (within 1 week before first session) and post-intervention (within 1 week after final sessionThe Vocal Fatigue Index (VFI) is a validated questionnaire designed to measure three distinct dimensions of vocal fatigue and voice disorders. It evaluates scores across three subscales: Fatigue and Avoidance (Part 1): Scores range from 0 to 44, with scores ≥24 indicating severity. Physical Discomfort (Part 2): Scores range from 0 to 20, with scores ≥7 indicating severity. Improvement with Rest (Part 3): Scores range from 0 to 12, with scores ≤7 indicating severity. Higher scores on Parts 1 and 2, and lower scores on Part 3, indicate greater voice disorder severity. The VFI is intended to be used for the score of each subscale individually and is not validated to measure severity based on the composite score. However, the maximum total score across all three subscales is 79.
CAPE-V, Consensus on Auditory-Perceptual Evaluation of VoicePre-intervention (within 1 week before first session) and post-intervention (within 1 week after final sessionA subjective auditory-perceptual evaluation to judge the severity of dysphonia from the standpoint of expert clinician raters (at least 2 for each sample, not including the treating clinician). Scale of severity overall from 0-100. Higher score indicates more severity of symptoms.
Heart rate measured in beats per minuteImmediately pre- and immediately post-meditation in each therapy session, over approximately 4 weeksHeart rate (HR) is measured in beats per minute (bpm) using a standard hospital-provided pulse oximeter to assess cardiovascular function.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORBradley R Hoff, MA, CCC-SLP

Icahn School of Medicine at Mount Sinai, Department of Otolaryngology

STUDY_DIRECTORÜmit Daşdöğen, Ph.D., CCC-SLP

Icahn School of Medicine at Mount Sinai, Department of Otolaryngology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026